TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18377706

Group type: EXPERIMENTAL
Intervention: MCID change group (placebo-treated patients)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (matched pairs)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: MCID change group
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study: 16671071

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 224
Study: 12797502

Group type: EXPERIMENTAL
Intervention: Pumactant (400 mg) administered in two doses (first dose 8 h before allergen exposure, second dose 30 min before exposure)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 7
Study: 10738706

Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone for 2 hours with intermittent exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 9
Study: 9039270

Group type: EXPERIMENTAL
Intervention: SP plus daily iron (SPD)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: SP plus weekly iron (SPW)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine only (SP)
Number of subjects: 222

Group type: COMPARATOR
Intervention: SPW and SP
Number of subjects: 222

Group type: COMPARATOR
Intervention: SP
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 222
Study: 8466728

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg twice daily)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Methyldopa + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368
Study: 3993534

Group type: EXPERIMENTAL
Intervention: Acebutolol, 400 mg once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Atenolol, 100 mg once daily
Number of subjects: 33
Study: 31661958

Group type: EXPERIMENTAL
Intervention: Kernel ridge regression with a training set of randomly selected 5% structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptors based on pore geometry barcodes
Number of subjects: 0
Study: 29064285

Group type: EXPERIMENTAL
Intervention: BT + OR
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: BT + OR + S
Number of subjects: 78

Group type: COMPARATOR
Intervention: BT
Number of subjects: 78
Study: 26859648

Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA-35%) peel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Salicylic-mandelic (SM) acid peel (20% salicylic/10% mandelic acid)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phytic combination peels
Number of subjects: 90
Study: 25222346

Group type: EXPERIMENTAL
Intervention: Split sleep condition (two 5-h sleeping opportunities in 24 h: 0300 h-0800 h and 1500 h-2000 h)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nighttime sleep condition (10-h consolidated nighttime sleep: TIB 2200 h-0800 h)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Daytime sleep condition (10-h consolidated daytime sleep: TIB 1000 h-2000 h)
Number of subjects: 53
Study: 22074766

Group type: EXPERIMENTAL
Intervention: Social smoking motive (characters smoked to facilitate social interaction)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Relaxation smoking motive (characters smoked to relax)
Number of subjects: 358

Group type: COMPARATOR
Intervention: No smoking motive (characters smoked with no apparent motive)
Number of subjects: 358
Study: 20731529

Group type: EXPERIMENTAL
Intervention: ATOR 20 mg up-titrated to 80 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ROSU 10 mg up-titrated to 40 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 80
Study: 19065859

Group type: EXPERIMENTAL
Intervention: Regions perceived as figures in ambiguous, bipartite, 2-D displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regions perceived as grounds in ambiguous, bipartite, 2-D displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regions perceived as grounds (holes) in nested displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unambiguous 3-D cardboard displays of objects versus holes
Number of subjects: 0
Study: 15865114

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Observation (watchful waiting)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cholecystectomy and Observation (watchful waiting)
Number of subjects: 64
Study: 12544987

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 10194146

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 54
Study: 8648539

Group type: EXPERIMENTAL
Intervention: 8-week exercise program and 8 weeks of classes on nutrition and smoking
Number of subjects: 1274
Study: 1735925

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with oral potassium
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with oral potassium and magnesium
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 233
Study: 3878109

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31499386

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Passive Static Stretching (SS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 29517189

Group type: EXPERIMENTAL
Intervention: Elastic band resistance training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 26472111

Group type: EXPERIMENTAL
Intervention: Minimally invasive, arthroscopically assisted, antero-lateral approach for cam resection
Number of subjects: 77
Study: 24727483

Group type: EXPERIMENTAL
Intervention: Extended, nontailored treatments (12 weeks of counseling, nicotine replacement, and bupropion)
Number of subjects: 777
Study: 20733579

Group type: EXPERIMENTAL
Intervention: CYT997 administered by continuous intravenous infusion over 24 h every 3 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CYT997 doses of >or=65 mg m(‐2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Higher dose levels of CYT997
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CYT997
Number of subjects: 31
Study: 15675980

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.5 mg kg(‐1) . h(‐1) administered intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (administered intravenously)
Number of subjects: 20
Study: 12085003

Group type: EXPERIMENTAL
Intervention: 750 microg of fluticasone propionate (FP) twice daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo twice daily for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 750 microg of fluticasone propionate (FP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9643616

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7604628

Group type: EXPERIMENTAL
Intervention: Local mitomycin-C (MTM-C) therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nd-YAG laser treatment
Number of subjects: 59
Study: 2844549

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.i.d. for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study: 11420579

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) plus standard medical therapy for CHF
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard medical therapy for CHF
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 408
Study: 31447514

Group type: EXPERIMENTAL
Intervention: Good basic knowledge of hypertension
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Good attitude towards hypertension
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Good self-care practice towards hypertension
Number of subjects: 385
Study: 30287422

Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1707
Study: 26945817

Group type: EXPERIMENTAL
Intervention: Antioxidant-pregabalin combination
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 24029220

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (exacerbation-free group)
Number of subjects: 0
Study: 22815019

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 60
Study: 20620618

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study: 17268908

Group type: EXPERIMENTAL
Intervention: Stented group (18 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stentless group (9 patients)
Number of subjects: 27
Study: 15248223

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice weekly, subcutaneous injection)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12472517

Group type: EXPERIMENTAL
Intervention: Betamethasone drops
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluticasone nasules
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study: 9638413

Group type: EXPERIMENTAL
Intervention: Multimodality therapy combining pancreatic resection with neo‐ and adjuvant locoregional targeting immunochemotherapy (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pancreatic surgery only (Group B)
Number of subjects: 26
Study: 7734455

Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 0
Study: 2492234

Group type: EXPERIMENTAL
Intervention: Leuprolide, 1 mg subcutaneously per day, administered from the midluteal phase before IVF treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prior IVF attempts without GnRHa suppression
Number of subjects: 26
Study: 4855496

Group type: EXPERIMENTAL
Intervention: Orotic acid (100 mg/kg/day) orally in 2 daily doses from 1st to 5th day of life
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 30227721

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 32-mm heads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 36-mm heads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 32-mm heads from 3 months to 6 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 36-mm heads from 3 months to 6 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Annual proximal wear rate for 32-mm heads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Annual proximal wear rate for 36-mm heads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone remodelling around the cup
Number of subjects: 40
Study: 27943522

Group type: EXPERIMENTAL
Intervention: TAP block with 40 ml of 0.25% bupivacaine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wound infiltration with 40 ml of 0.25% bupivacaine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups (TAP and control)
Number of subjects: 71
Study: 25378135

Group type: EXPERIMENTAL
Intervention: Intravenous firocoxib (57 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral paste firocoxib (57 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral tablet firocoxib (57 mg)
Number of subjects: 6
Study: 22841520

Group type: EXPERIMENTAL
Intervention: metformin (3 g daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 22089303

Group type: EXPERIMENTAL
Intervention: Mizone Rapid (hypotonic)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PowerAde (isotonic)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gatorade (hypertonic)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 11
Study: 18157674

Group type: EXPERIMENTAL
Intervention: Topical steroid cream (monometasone furoate 0.1%) applied twice a day for 4 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo cream applied twice a day for 4 weeks
Number of subjects: 240
Study: 16421647

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcitonin 100 IU daily
Number of subjects: 63
Study: 15231471

Group type: EXPERIMENTAL
Intervention: GE 400 ultrasound machine
Number of subjects: 49

Group type: COMPARATOR
Intervention: SonoSite 180 Plus ultrasound machine
Number of subjects: 49
Study: 10772301

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Symptoms suggestive of OSAS
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Observation period
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Adenoidectomy alone
Number of subjects: 58
Study: 9557074

Group type: EXPERIMENTAL
Intervention: Children from HTG families
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control children from healthy families
Number of subjects: 41
Study: 8317643

Group type: EXPERIMENTAL
Intervention: Pancuronium 1 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline pretreatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pancuronium pretreatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 200
Study: 3519879

Group type: EXPERIMENTAL
Intervention: melphalan and prednisone (MP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: prednisone, Adriamycin, azathioprine, and vincristine (PAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: no therapy until relapse, then treatment with BCP
Number of subjects: 0
Study: 30099128

Group type: EXPERIMENTAL
Intervention: Desmopressin for monosymptomatic NE
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Oxybutynin for nonmonosymptomatic NE with overactive bladder
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Overall treatment response for NE
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Response to LUTS treatment
Number of subjects: 184
Study: 26433217

Group type: EXPERIMENTAL
Intervention: Active 10-Hz rTMS applied to the left DLPFC for 3 weeks (15 sessions, 1000 stimuli per session)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 156
Study: 25532971

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 22758791

Group type: EXPERIMENTAL
Intervention: Protamine zinc recombinant human insulin (PZIR) at 0.3 U/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protamine zinc recombinant human insulin (PZIR) at 0.5 U/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protamine zinc recombinant human insulin (PZIR) at 0.8 U/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protamine zinc recombinant human insulin (PZIR) at 0.8 U/kg at three separate sites
Number of subjects: 10
Study: 20484549

Group type: EXPERIMENTAL
Intervention: Diet rich in fruits and vegetables
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Natural menopause
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Moderate exercise (walking and gardening)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Heavy physical activity in one's 20s
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Breast cancer in a first-degree relative
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: History of prior benign breast lumps
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Numbers of BSE per year
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Years of education
Number of subjects: 327
Study: 17921185

Group type: EXPERIMENTAL
Intervention: Abatacept (approximately 10 mg/kg)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 16463820

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 737

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 737
Study: 12075267

Group type: EXPERIMENTAL
Intervention: QRS duration > or = 120 ms
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: QRS duration > or = 120 ms in patients with EF <30%
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: QRS duration > or = 120 ms in patients with EF 30% to 40%
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Left bundle branch block
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Prolongation of QRS
Number of subjects: 669
Study: 9888410

Group type: EXPERIMENTAL
Intervention: OTZ (70 mg/kg IV every 8 hours for 9 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cirrhosis patients (compared to controls)
Number of subjects: 9
Study: 7746775

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 500 micrograms (two puffs of Becloforte) with a 750 ml spacer
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate (BDP) 500 micrograms (two puffs of Becloforte) without a spacer
Number of subjects: 26
Study: 1981319

Group type: EXPERIMENTAL
Intervention: UK-52,046 (0.4 microgram kg‐1 i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prazosin (0.25 mg i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: UK-52,046
Number of subjects: 6
Study: 6102230

Group type: EXPERIMENTAL
Intervention: Mepivacaine 0.5%
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 53
Study: 30786254

Group type: EXPERIMENTAL
Intervention: Milking of the umbilical cord (4 times before clamping)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Delayed clamping (60 seconds)
Number of subjects: 204
Study: 29037638

Group type: EXPERIMENTAL
Intervention: Clinical Pilates exercise (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional exercise (n = 16)
Number of subjects: 33
Study: 26047385

Group type: EXPERIMENTAL
Intervention: PHEMA (poly(2-hydroxyethylmethacrylate))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Histoacryl/lipiodol mixture
Number of subjects: 18
Study: 23681930

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21510864

Group type: EXPERIMENTAL
Intervention: Low fortification breakfast cereal
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Moderate fortification breakfast cereal
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High fortification breakfast cereal
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no fortification)
Number of subjects: 73
Study: 19464535

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination with 3.0 microg HA
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination with 4.5 microg HA
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination with 6.0 microg HA
Number of subjects: 224

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) vaccination with 15.0 microg HA
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination
Number of subjects: 224

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) vaccination
Number of subjects: 224
Study: 17207036

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 116
Study: 15190444

Group type: EXPERIMENTAL
Intervention: Endoscopic assessment of Barrett's esophagus length
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Histological assessment of Barrett's esophagus area from 4QB
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation between endoscopic and histological assessment
Number of subjects: 75
Study: 11689037

Group type: EXPERIMENTAL
Intervention: Isometric force contractions with visual feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isometric force contractions without visual feedback
Number of subjects: 48
Study: 9424929

Group type: EXPERIMENTAL
Intervention: PGE-1
Number of subjects: 0
Study: 7957006

Group type: EXPERIMENTAL
Intervention: Soybean oil plus psyllium fibre (20 g/day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Coconut oil plus psyllium fibre (20 g/day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Soybean oil diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Coconut oil diet
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Psyllium supplementation periods
Number of subjects: 4